Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ulrich Hoffmann

Showing results (101-110 of 105) with videos related to

Pageof 11
Sort By:
You have reached the last page of results.This site can display upto 105 results.
Thrombosis and Haemostasis|January 17, 2025
Treatment of Venous Thromboembolism with Edoxaban over 18 Months: Results from ETNA-VTE EuropeGiancarlo Agnelli, Ulrich Hoffmann, Philippe Hainaut, et al.
European Journal of Internal Medicine|August 23, 2020
ETNA VTE Europe: A contemporary snapshot of patients treated with edoxaban in clinical practice across eight European countriesAlexander T Cohen, Ulrich Hoffmann, Philippe Hainaut, et al.
Thrombosis Research|September 20, 2020
ETNA-VTE Europe: Benefits and risks of venous thromboembolism treatment using edoxaban in the first 3 monthsGiancarlo Agnelli, Ulrich Hoffmann, Philippe Hainaut, et al.
Thrombosis Journal|May 3, 2018
Design and rationale of the non-interventional, edoxaban treatment in routiNe clinical prActice in patients with venous ThromboEmbolism in Europe (ETNA-VTE-Europe) studyAlexander T Cohen, Cihan Ay, Philippe Hainaut, et al.
Thrombosis Journal|June 2, 2018
Correction to: Design and rationale of the non-interventional, edoxaban treatment in routiNe clinical prActice in patients with venous ThromboEmbolism in Europe (ETNA-VTE-Europe) studyAlexander T Cohen, Cihan Ay, Philippe Hainaut, et al.
Pageof 11

Showing results (101-110 of 105) with videos related to

Sort By:
Pageof 11
You have reached the last page of results.This site can display upto 105 results.
Thrombosis and Haemostasis|January 17, 2025
Treatment of Venous Thromboembolism with Edoxaban over 18 Months: Results from ETNA-VTE EuropeGiancarlo Agnelli, Ulrich Hoffmann, Philippe Hainaut, et al.
European Journal of Internal Medicine|August 23, 2020
ETNA VTE Europe: A contemporary snapshot of patients treated with edoxaban in clinical practice across eight European countriesAlexander T Cohen, Ulrich Hoffmann, Philippe Hainaut, et al.
Thrombosis Research|September 20, 2020
ETNA-VTE Europe: Benefits and risks of venous thromboembolism treatment using edoxaban in the first 3 monthsGiancarlo Agnelli, Ulrich Hoffmann, Philippe Hainaut, et al.
Thrombosis Journal|May 3, 2018
Design and rationale of the non-interventional, edoxaban treatment in routiNe clinical prActice in patients with venous ThromboEmbolism in Europe (ETNA-VTE-Europe) studyAlexander T Cohen, Cihan Ay, Philippe Hainaut, et al.
Thrombosis Journal|June 2, 2018
Correction to: Design and rationale of the non-interventional, edoxaban treatment in routiNe clinical prActice in patients with venous ThromboEmbolism in Europe (ETNA-VTE-Europe) studyAlexander T Cohen, Cihan Ay, Philippe Hainaut, et al.
Pageof 11